Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma(PNOC018) | terminated | Phase 1 | 4 | University of California, San FranciscoOTHER | 1 | Jul 13, 2026 |
| clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03866109 | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT(TEM-GBM) | terminated | Phase 1 / Phase 2 | 25 | Genenta ScienceINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | terminated | Phase 1 / Phase 2 | 70 | VBI Vaccines Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | terminated | Phase 1 | 7 | Nicholas ButowskiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03334305 | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas(ACTION) | terminated | Phase 1 | 18 | University of FloridaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT01795313 | Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod | terminated | Phase 1 | 23 | James FelkerOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | terminated | Phase 1 | 29 | Taiho Oncology, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | terminated | Phase 1 | 44 | Day One Biopharmaceuticals, Inc.INDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04963413 | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | terminated | Phase 1 | 6 | University of FloridaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT01324635 | Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors | terminated | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas | terminated | Phase 1 / Phase 2 | 7 | Dawonmedax Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | terminated | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | terminated | Phase 1 | 134 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma(MAGIC-G1) | terminated | Phase 1 | 4 | Biodexa PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)(KONQUER) | terminated | Phase 1 | 10 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 74 | Karyopharm Therapeutics IncINDUSTRY | 2 | Dec 16, 2024 | clinicaltrials |
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers | terminated | Phase 1 | 27 | Guido A. Davidzon, MD, SMOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 184 | CelgeneINDUSTRY | 7 | Jul 26, 2024 | clinicaltrials |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM | terminated | Phase 1 / Phase 2 | 8 | SonALAsense, Inc.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 | 20 | CelgeneINDUSTRY | 2 | Jul 5, 2024 | clinicaltrials |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 26 | Basilea PharmaceuticaINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | terminated | Phase 1 | 14 | Nicholas ButowskiOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | terminated | Phase 1 / Phase 2 | 5 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM | terminated | Phase 1 / Phase 2 | 8 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | terminated | Phase 1 | 3 | Monteris MedicalINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | terminated | Phase 1 | 7 | Providence Health & ServicesOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05394558 | AsiDNA Children, Adolescents and Young Adults(AsiDNA) | terminated | Phase 1 / Phase 2 | 8 | Institut CurieOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | terminated | Phase 1 | 4 | University of NebraskaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02833701 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | terminated | Phase 1 | 9 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02659800 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | terminated | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials